Literature DB >> 10617123

Effect of Congo red on wild-type and mutated prion proteins in cultured cells.

O Milhavet1, A Mangé, D Casanova, S Lehmann.   

Abstract

Transmissible spongiform encephalopathies form a group of fatal neurodegenerative disorders that have the unique property of being infectious, sporadic, or genetic in origin. Although some doubts remain on the nature of the responsible agent of these diseases, it is clear that a protein called PrP(Sc) (which stands for the scrapie isoform of the prion protein) has a central role in their pathology. PrP(Sc) represents a conformational variant of a normal protein of the host: the cellular isoform of the prion protein, or PrP(C). Compounds such as glycosaminoglycans and Congo red (CR) have been shown to interfere with both in vitro and in vivo PrP(Sc) formation. It was hypothesized that CR acts by overstabilizing the conformation of PrP(Sc) molecules or by modifying trafficking of PrP(C). Using transfected cells expressing 3F4-tagged mouse PrPs, we show here that CR does not interfere with conversion of PrP molecules carrying pathogenic mutations. On the contrary, after incubation with the drug, some of their properties, such as insolubility and protease resistance, are enhanced and are even acquired by the wild-type molecule. This last observation suggests an alternative mechanism of action of CR and leads us to reconsider the relationship between the biochemical properties of PrP and conformational alteration of the protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617123     DOI: 10.1046/j.1471-4159.2000.0740222.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.

Authors:  A Mangé; N Nishida; O Milhavet; H E McMahon; D Casanova; S Lehmann
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.

Authors:  Ilan Margalith; Carlo Suter; Boris Ballmer; Petra Schwarz; Cinzia Tiberi; Tiziana Sonati; Jeppe Falsig; Sofie Nyström; Per Hammarström; Andreas Aslund; K Peter R Nilsson; Alice Yam; Eric Whitters; Simone Hornemann; Adriano Aguzzi
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

3.  Evaluation of quinacrine treatment for prion diseases.

Authors:  A Barret; F Tagliavini; G Forloni; C Bate; M Salmona; L Colombo; A De Luigi; L Limido; S Suardi; G Rossi; F Auvré; K T Adjou; N Salès; A Williams; C Lasmézas; J P Deslys
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Authors:  Sarah Webb; Tamuna Lekishvili; Corinna Loeschner; Shane Sellarajah; Frances Prelli; Thomas Wisniewski; Ian H Gilbert; David R Brown
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

5.  Hot spots in prion protein for pathogenic conversion.

Authors:  Kazuo Kuwata; Noriyuki Nishida; Tomoharu Matsumoto; Yuji O Kamatari; Junji Hosokawa-Muto; Kota Kodama; Hironori K Nakamura; Kiminori Kimura; Makoto Kawasaki; Yuka Takakura; Susumu Shirabe; Jiro Takata; Yasufumi Kataoka; Shigeru Katamine
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-06       Impact factor: 11.205

Review 6.  Pharmacological Agents Targeting the Cellular Prion Protein.

Authors:  Maria Letizia Barreca; Nunzio Iraci; Silvia Biggi; Violetta Cecchetti; Emiliano Biasini
Journal:  Pathogens       Date:  2018-03-07

Review 7.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.